Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial.

Dermatol Ther (Heidelb) · 2026 · PMC13280320 · PMID 42151643

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although these differences did not reach statistical significance, likely because of the limited sample size, the directionally consistent findings across endpoints provide preliminary evidence supporting the potential efficacy of HDM3010 in PN.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.